A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 06 May 2016
At a glance
- Drugs Tefinostat (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 19 Mar 2016 Planned End Date changed from 31 Jan 2016 to 31 May 2016 as reported by United Kingdom Clinical Research Network.
- 10 Dec 2015 Planned End Date changed from 31 Jul 2015 to 31 Jan 2016 according to United Kingdom Clinical Research Network record.
- 05 Mar 2015 Accrual to date is 21% according to United Kingdom Clinical Research Network record.